白云山(600332.SH)：“大南药”研发平台建设项目结项及节余募集资金永久补充流动资金

Core Viewpoint - The company has completed the fundraising project for the "Danan Pharmaceutical" R&D platform, marking the conclusion of all fundraising projects from its 2016 non-public A-share issuance [1] Group 1 - The remaining funds from the "Danan Pharmaceutical" R&D platform amount to 285.5186 million RMB [1] - The remaining funds from the first phase of the "Danan Pharmaceutical" production base total 133.4185 million RMB [1] - A total of 418.9371 million RMB will be permanently used to supplement working capital for production and business development related to the company's main operations [1]